Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than Individual Gene Expression Levels

Pathway Instability Is an Effective New Mutation-Based Type of Cancer Biomarkers

(2019) Marianna A. Zolotovskaia et al.   Frontiers in Oncology

RNA sequencing analysis for profiling activation of cancer-associated molecular pathways.

(2019) Anton Buzdin et al.   JOURNAL OF CLINICAL ONCOLOGY

Atlas of RNA sequencing profiles for normal human tissues

(2019) Maria Suntsova et al.   Scientific Data

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

(2019) Sabine Schmid et al.   BMC CANCER

RNA sequencing for research and diagnostics in clinical oncology

(2019) Anton Buzdin et al.   SEMINARS IN CANCER BIOLOGY

H3K4me3, H3K9ac, H3K27ac, H3K27me3 and H3K9me3 Histone Tags Suggest Distinct Regulatory Evolution of Open and Condensed Chromatin Landmarks

(2019) Anna A. Igolkina et al.   Cells

PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer

(2019) William P. D. Hendricks et al.   Cancers

Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors

(2019) Elena Poddubskaya et al.   Frontiers in Oncology

Differences in Breast Cancer Survival by Molecular Subtypes in the United States

(2018) Nadia Howlader et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment

(2018) Naveen Kumar et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging

(2018) Tingting Liu et al.   NEURORADIOLOGY

Molecular pathway activation – New type of biomarkers for tumor morphology and personalized selection of target drugs

(2018) Anton Buzdin et al.   SEMINARS IN CANCER BIOLOGY

Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2–positive breast cancer

(2018) Johan M. van Rooijen et al.   EUROPEAN JOURNAL OF CANCER

Relationship between HER2 gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment

(2018) Agnieszka Adamczyk et al.   OncoTargets and Therapy

EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis

(2018) Long Chen et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III

(2018) Mariana Marggraf et al.   Marine Drugs

Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles

(2017) Vanesa G. Martinez et al.   OncoImmunology

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99

(2016) O. Pagani et al.   ANNALS OF ONCOLOGY

Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies

(2016) H S Okuma et al.   BRITISH JOURNAL OF CANCER

MiRImpact, a new bioinformatic method using complete microRNA expression profiles to assess their overall influence on the activity of intracellular molecular pathways

(2016) Alina V. Artcibasova et al.   CELL CYCLE

In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development

(2016) Ivan V. Ozerov et al.   Nature Communications

RNA-Seq versus oligonucleotide array assessment of dose-dependent TCDD-elicited hepatic gene expression in mice

(2015) Rance Nault et al.   BMC GENOMICS

Targeted therapy in her2-positive metastatic breast cancer: a review of the literature

(2015) X. Zhu et al.   Current Oncology

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial

(2015) Amir Sonnenblick et al.   Oncotarget

A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation

(2015) Artem Artemov et al.   Oncotarget

Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways

(2015) Ksenia Lezhnina et al.   Oncotarget

Signaling pathways activation profiles make better markers of cancer than expression of individual genes

(2015) Nikolay M. Borisov et al.   Oncotarget

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer

(2014) Aleix Prat et al.   JNCI-Journal of the National Cancer Institute

A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium

(2014)   NATURE BIOTECHNOLOGY

The Reactome pathway knowledgebase

(2013) David Croft et al.   NUCLEIC ACIDS RESEARCH

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models

(2010)   NATURE BIOTECHNOLOGY

The KDEL receptor: New functions for an old protein

(2009) Mirco Capitani et al.   FEBS LETTERS

PID: the Pathway Interaction Database

(2008) Carl F. Schaefer et al.   NUCLEIC ACIDS RESEARCH